Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2024-03-04 Share Issue/Capital Cha…
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)
Share Issue/Capital Change Classification · 99% confidence The document announces that Vistin Pharma ASA has acquired a minority share in CF Pharma Kft. This is a specific corporate action related to business development, partnership, and expansion of the product portfolio. This type of announcement, detailing a merger, acquisition, or significant strategic transaction, aligns best with the 'M&A Activity' category (TAR). It is not a standard financial report (10-K, IR, ER), a management change (MANG), or a financing event (CAP). Given the nature of acquiring a stake in another company, TAR is the most appropriate classification.
2024-03-04 English
Vistin Pharma ASA: Key information relating to the proposed cash dividend
Notice of Dividend Amount Classification · 100% confidence The document explicitly details the proposal for a cash dividend, specifying the amount per share (NOK 0.50 for June and NOK 0.50 for November), the accounting year (2023), and key dates such as the Ex-date, Record date, and Payment date for both proposed installments. This content directly corresponds to the definition of a 'Notice of Dividend Amount' (DIV). It is not an AGM presentation (AGM-R), a full annual report (10-K), or a general earnings release (ER). The document is short and focuses solely on the dividend details.
2024-02-16 English
Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the fourth quarter and full year 2023, titled '4TH QUARTER REPORT AND PRELIMINARY FINANCIALS FOR 2023'. It contains detailed financial statements, including revenue, EBITDA, cash flow, balance sheet data, and management commentary on operational status and risks. It is not a mere announcement (RPA) or a short summary, as it provides substantive financial data and analysis for an interim period. Q4 2023
2024-02-16 English
Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results
Investor Presentation Classification · 95% confidence The document is structured as a presentation, featuring slides/sections titled 'Highlights', 'Market overview', 'Financial review', 'Strategy', and 'Appendix'. It contains detailed financial figures for Q4 2023 and FY 2023, including income statement and balance sheet tables, and discusses strategy and future outlook. The date is February 16, 2024. This content strongly suggests a presentation given during or in preparation for an Annual General Meeting (AGM) or a detailed investor presentation covering annual results. Since it contains the full financial review and strategy presentation format, it aligns best with an Investor Presentation (IP) or AGM material. Given the comprehensive nature covering the full year's performance and strategy, and the explicit mention of a proposed ordinary dividend for the AGM, 'Investor Presentation' (IP) is the most fitting classification for this presentation deck format, although 'AGM-R' is also plausible if this was the exact deck used at the meeting. Since it is a detailed presentation deck, IP is chosen over AGM-R which is usually reserved for the formal meeting materials/minutes.
2024-02-16 English
Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results
Earnings Release Classification · 100% confidence The document explicitly announces the 'Fourth quarter and preliminary 2023 financial results' for Vistin Pharma ASA, providing key financial highlights such as revenue (MNOK 111 in Q4), EBITDA (MNOK 25 in Q4), and net profit (MNOK 18 in Q4). This content structure—a summary of period-specific financial performance—is characteristic of an Earnings Release (ER). Although it mentions that the full Q4 report and presentation are enclosed, the document itself is the initial announcement of the results, making ER the most appropriate classification based on the provided definitions. It is too detailed for a simple RPA, and it is not the full comprehensive report (IR) or the management discussion (MDA). Q4 2023
2024-02-16 English
Vistin Pharma ASA: Invitation to Q4 2023 conference call
Call Transcript Classification · 90% confidence The document is an invitation from Vistin Pharma ASA announcing the release of their Q4 2023 results and scheduling a subsequent conference call for shareholders and interested parties, including a Q&A session. This announcement explicitly details the date, time, and access links (webcast and telephone registration) for the conference call where management will discuss the results. This perfectly matches the definition of a Call Transcript (CT) in terms of the event being announced, but the document itself is the *invitation* to the call, not the transcript or the earnings release highlights. Since the document is short (1501 chars) and serves to announce an upcoming event where a transcript will be generated, it is most accurately classified as an announcement related to a corporate event. However, given the options, an invitation to an earnings-related conference call strongly suggests the content is preparatory to or directly related to the earnings discussion. The most fitting category for the *event* being promoted is the Call Transcript (CT), as the primary purpose is to drive attendance to the call itself. If the document were the actual earnings highlights, it would be ER. If it were the full transcript, it would be CT. Since it is an invitation to the call, it is closely related to the CT event. Alternatively, it could be RNS as a general announcement. Given the specific nature of announcing a conference call with Q&A, CT is the most specific fit for the *type of event* being publicized, even if this specific document is the invitation.
2024-02-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.